🇺🇸 FDA
Patent

US 11311574

Methods and compositions for targeted cleavage and recombination

granted A61KA61K2035/124A61K35/12

Quick answer

US patent 11311574 (Methods and compositions for targeted cleavage and recombination) held by Sangamo Therapeutics, Inc. expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2035/124, A61K35/12